The PI3K-GS, derived in vitro, was based on repression or induction as a result of treatment with PI3K inhibitors, whereas the PTEN-loss-GS recapitulates IHC-detectable loss and could be more appropriate for use in studies of basal-like tumours, in which it is associated with high pathway activity [37]. This evidence concerns the gene PIK3CA and neoplasm.